Case 1: on March 31st, a 46 years old male patient, with a previous history of mild depressive episode treated with vortioxetine since November 2019, and diagnosed with COVID-19 after he presented with dry cough, fever, sore throat and fatigue. The patient had positive result on reverse transcription polymerase chain reaction (PCR) analysis of nose swab specimen. He was admitted into isolated COVID-19 ward and received chloroquine- azithromycine association. He had an electrocardiogram every two days. QT interval was normal to prolonged (corrected QT max: 490ms). On the ninth day of treatment, the patient showed symptoms of distress and insomnia. On the evening of the same day, he showed abrupt onset of psychotic symptoms such as visual hallucinations and incoherent speech, with the outburst of odd behavior and repeated attempts to run away from hospital. The patient s insight was preserved. The cerebral CT scan was normal. We performed laboratory tests: ionogram, blood count, differential coagulation times, serum glucose, creatinine, sodium, potassium, liver enzymes, HIV, VHB, VHC and Syphilis serologies, who turned out to be normal. We made the decision to interrupt COVID-19 medication protocol as well as vortioxetine, and we initiate amilsulpride at the dose of 100 mg per day. Psychotic symptoms disappeared totally after 48 hours. We tapered off and then stopped amilsulpride within a week. The patient remained asymptomatic, and we evaluated him once in two weeks. On the latest psychiatric assessment (May 20), the patient showed no psychotic symptoms.